← Leaderboards
Ovidiu C Andronesi
Massachusetts General Hospital
$8,946,091
Attributed
$8,946,091
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,946,091 · 4
By mechanism
R01$7,744,703 · 2
K22$601,388 · 1
S10$600,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Daniel P. Cahill$3,140,317
- Gilbert J Rahme$1,218,149
- Supriya K Saha$1,502,420
- Hiroaki Wakimoto$2,299,893
- Sita Kugel$5,881,835
Others in their field
Top investigators on “Image”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$332,241,999
- Leonard Freedman · Leidos Biomedical Research, Inc.$321,574,964
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$217,904,052
- Ethan Schreier · Associated Universities, Inc.$206,468,864
Research focus
ImageInnovationMalignant NeoplasmsMolecular ImagingMissionCancer ImagingImaging DeviceDiagnosisSurvival RateBiopsyMutationIn VivoImaging ModalityTumorCancer TherapyTreatment ResponseGliomaMutantIsocitrate DehydrogenaseImproved OutcomePublic HealthMolecularChemoradiationLongitudinal Studies
Grant awards (17)
Development of multinuclear MRI for image guided therapy of glioma patients$701,639
R01 · FY2025 · CA · contact PI
Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients$679,074
R01 · FY2025 · CA · contact PI
Development of multinuclear MRI for image guided therapy of glioma patients$682,470
R01 · FY2024 · CA · contact PI
Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients$645,121
R01 · FY2024 · CA · contact PI
Development of multinuclear MRI for image guided therapy of glioma patients$616,798
R01 · FY2023 · CA · contact PI
Multinuclear imaging for clinical 7T MRI$600,000
S10 · FY2023 · OD · contact PI
Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients$561,070
R01 · FY2023 · CA · contact PI
Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients$554,297
R01 · FY2022 · CA · contact PI
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH glioma$586,772
R01 · FY2021 · CA · contact PI
Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients$569,946
R01 · FY2021 · CA · contact PI
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH glioma$641,772
R01 · FY2020 · CA · contact PI
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH glioma$358,913
R01 · FY2019 · CA · contact PI
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH glioma$530,585
R01 · FY2018 · CA · contact PI
Development of whole-brain in vivo 2HG imaging for precision medicine in mutant IDH glioma$616,246
R01 · FY2017 · CA · contact PI
Quantify treatment response in IDH1 mutant glioma patients with metabolic MRI$200,418
K22 · FY2016 · CA · contact PI
Quantify treatment response in IDH1 mutant glioma patients with metabolic MRI$200,418
K22 · FY2015 · CA · contact PI
Quantify treatment response in IDH1 mutant glioma patients with metabolic MRI$200,552
K22 · FY2013 · CA · contact PI